Whilst we are waiting on RC220 trial kick off I was thinking about how results in vitro will translate into the clinic. Apart from the fact it’s not clinical validation how likely or unlikely do you think it is?
I guess the main areas are cardio protection and FTO as anti-cancer has already been observed in historical trials for AML.
Just trying to gauge the room, whether you feel RC220 will or won’t work in the clinic? Throw out some percentages
FTO translation: %
Cardio Protect: %
Good to understand where this sits with everyone
and why?…
General Comments / Chat, page-10117
-
- There are more pages in this discussion • 901 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
0.105(6.14%) |
Mkt cap ! $309.0M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.96 | $1.75 | $862.1K | 467.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |